Cost-Effectiveness Analysis of a Bivalent RSVPreF Vaccine in Japanese Adults Aged 60 Years and Older
{{output}}
Introduction: Respiratory syncytial virus (RSV) is a major cause of acute respiratory illness. A bivalent RSV prefusion F protein-based (RSVpreF) vaccine was approved in Japan to prevent RSV-related diseases in older adults in 20... ...
